Lang, Chim


  • Source: Scopus
  • Calculated based on no. of publications stored in Pure and citations from Scopus
1985 …2022

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile


Full contribution to teaching in Dundee, especially cardiology and clinical pharmacology. External undergraduate examinerships (National University of Singapore, University of Malaya, International Medical University, Malaysia, National University of Malaysia). Supervisor of 25 MD/PhDs personally. External examiner for PhD/ MD (Universities of Birmingham, Cardiff, Edinburgh, Glasgow, Aberdeen, Hull)


Professor Lang is a consultant cardiologist and clinical pharmacologist and Professor of Cardiology at Ninewells Hospital and Medical School, Dundee, United Kingdom. He trained in both cardiology and clinical pharmacology in the United Kingdom and in the United States where he was a Merck International Fellow in Clinical Pharmacology at Vanderbilt University, Nashville and a Fulbright Scholar at Columbia University, New York. He is a Fellow of the Royal Colleges of Physicians of London and Edinburgh and the American College of Cardiology and European Society of Cardiology.


Professor Lang is a translational cardiologist with a track record of research excellence in the area of cardio-metabolic diseases. He has published >250 papers in major journals, including NEJM, Lancet, European Heart Journal, JACC and Circulation. His research takes a multi-disciplinary approach to the understanding of the pathophysiology and pharmacogenetics of cardiovascular diseases and to the development of treatment strategies in patients with cardiovascular diseases. He leads an integrated cardiovascular research laboratory dedicated and equipped to the study of cardiac and vasomotor regulation. These techniques are applied towards translational research and in the development of biomarkers and novel treatment strategies in patients with cardiovascular diseases. Prof Lang is WP Co-Lead in the €12.3M IMI2-CARDIATEAM project on diabetic cardiomyopathy and was WP lead in the €11.9M FP-7 BIOSTAT system biology project on heart failure and is the Chief Investigator of the BHF funded MET-REMODEL and RECEDE trials and the EFSD funded REFORM trial. He is also the lead Applicant of the MRC funded MRC UK-Malaysia Partnership on the Precision medicine for diabetic Individuals: a joint Malaysia-UK Effort (PRIME) project. He is the UK National Coordinator of the multi-international COMMANDER-HF and SELECT trials. A wide range of funding bodies including the British Heart Foundation, MRC, Chief Scientist Office, EASD, Chest Heart and Stroke Scotland, Tenovus and the European commission Seventh Framework (FP-7) and Horizon 2020 Programmes funds his research. 


Research interests

Undertaking research on COVID-19 to address the current coronavirus pandemic.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 2 - Zero Hunger
  • SDG 3 - Good Health and Well-being
  • SDG 7 - Affordable and Clean Energy

Education/Academic qualification

Doctor of Medicine

Award Date: 17 Jul 1993

Bachelor of Medicine and Bachelor of Surgery

Award Date: 1 Jan 1985

Bachelor of Science

Award Date: 1 Jan 1982


  • RM Therapeutics. Pharmacology
  • Cardiology


Dive into the research topics where Chim Lang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or